NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science  by Cairo, Mitchell S. et al.
REPORTFrom the
Colum
New
2Depa
of Roc
Institu
Onco
5Depa
Einste
York;
Institu
7Depa
Medic
Cell T
Hous
Depar
Pittsb
BetheNCI First International Workshop on the Biology,
Prevention, and Treatment of Relapse After Allogeneic
Hematopoietic Stem Cell Transplantation: Report from
the Committee on the Biological Considerations of
Hematological Relapse following Allogeneic Stem Cell
Transplantation Unrelated to Graft-versus-Tumor
Effects: State of the Science
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Scott A. Armstrong,6 Warren Shlomchik,7 Jeff Molldrem,8 Soldano Ferrone,9
Crystal Mackall,10 Laurence Zitvogel,11 Michael R. Bishop,12 Sergio A. Giralt,13 Carl H. June14Hematopoietic malignant relapse still remains the major cause of death following allogeneic hematopoietic
stem cell transplantation (HSCT). Although there has been a large focus on the immunologic mechanisms
responsible for the graft-versus-tumor (GVT) effect or lack thereof, there has been little attention paid to
investigating the biologic basis of hematologic malignant disease relapse following allogeneic HSCT. There
are a large number of factors that are responsible for the biologic resistance of hematopoietic tumors
following allogeneic HSCT. We have focused on 5 major areas including clonal evolution of cancer drug re-
sistance, cancer radiation resistance, genomic basis of leukemia resistance, cancer epigenetics, and resistant
leukemia stem cells. We recommend increased funding to pursue 3 broad areas that will significantly enhance
our understanding of the biologic basis of malignant relapse after allogeneic HSCT, including: (1) genomic and
epigenetic alterations, (2) cancer stem cell biology, and (3) clonal cancer drug and radiation resistance.
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mechanism(s) responsible for the graft-versus-tumor
(GVT) effect post-AlloHSCT and the multiple immu-
nologic factors responsible for hematologic relapse.
There are, however, a large number of biologic factors
of the host’s hematologic malignancy and/or the host’s
nonimmunologic genetic predisposition that may also
contribute significantly to the risk of hematologic
malignancy relapse post-AlloHSCT. To cover all
of the possibilities in this review would be too exhaus-
tive. Therefore, we elected to review the following
5 contemporary mechanisms that may contribute
to the risk of hematologic malignancy relapse post-
AlloHSCT including: cancer drug resistance, cancer
radiation resistance, cancer stem cells (CSCs), genomic
basis of leukemic relapse, and cancer epigenetics. We
will review the past accomplishments in these areas,
current ongoing investigations, and most importantly,
the critical research that will need to be pursued in the
next 5 years to optimally understand the nonimmuno-
logic mechanisms responsible for relapse, identify pre-
ventive strategies for hematologic relapse, and develop
therapeutic strategies to treat hematologic relapse.CLONAL EVOLUTION OF CANCER DRUG
RESISTANCE
Neoplastic cells acquire epigenetic and genetic
alterations including point mutations, small insertions
and deletions, translocations, large-scale copy number
changes, and loss of heterozygosity, as well as hyper-
and hypomethylation of promoter regions [1-8]. All
of these alterations are heritable; that is, when a cell
divides, its daughter cells inherit the alterations.
These somatic alterations generate (epi)genetic
heterogeneity within a neoplasm, and because some
of those alterations change the fitness (proliferation
rate and/or survival) of the cell, natural selection
ensues. This is the basis of neoplastic progression [9-
11]: a population of self-renewing cells acquire somatic
alterations, and clones with alterations that give them
a fitness advantage will tend to expand at the expense
of their normal and neoplastic competitor cells.
A therapeutic intervention changes the microenvi-
ronment of a neoplasm and changes the selective
pressures on those cells. Suddenly, the fitnesses of
the different (epi)genetic clones in the neoplastic cell
population change, and any cells that can survive and
proliferate better than their competitors under the
therapeutic exposure will tend to dominate the
remaining neoplasm. An intervention designed to kill
neoplastic cells will impose a huge selective pressure
on the cell population. Because the rate of evolution
depends in part on the fitness differential between cells,
resistant cells should rapidly attain high frequency in
the neoplasm.Forms of Drug Resistance
There are many reasons why conditioning therapy
prior to AlloHSCT may fail and result in hematologic
malignant relapse. An agent may have no effect on the
neoplastic cells, or the therapeutic index may be too
low to enable destruction of the neoplasm while pre-
serving normal cells. Some neoplastic cells may reside
in ‘‘refugia,’’ where a drug cannot penetrate. Survival
signals and other components of the microenviron-
ment may prevent apoptosis of some neoplastic cells.
Or, as alluded to earlier, an agent may select for an
(epi)genetic variant clone that is relatively resistant to
the drug.
Some forms of resistance are easier to manage than
others. If the agent has no activity against the disease,
then there is little to be done other than try a different
agent. This should be clear in a lack of therapeutic
response, although that might also indicate inadequate
concentration of the drug. If the patient does not show
any complications from the toxicity of the drug,
a higher concentration might be attempted. If resis-
tance is because of a failure of drug delivery to all of
the neoplasm or to protective effects of isolated micro-
environments, then when the patient relapses, the
same drug may be used again with the expectation of
similar efficacy. However, clinical experience has
shown that when a therapy is repeated on patients at
relapse, it generally has reduced efficacy. This is
a sign that the therapy has selected for resistant clones.
This may include selection for clones that generate
protective microenvironments for themselves. Selec-
tion for acquired therapeutic resistance is probably
the hardest form of resistance to deal with. We often
end up in a losing battle with evolution.Evolution of Acquired Resistance
The field of acquired therapeutic resistance in
cancer is still relatively small. Only a few genetic
alterations have been identified that are responsible
for therapeutic resistance. Gain of function point
mutations have been found to cause resistance in
BCR-ABL under imatinib (Gleevec) and dasatinib
(Sprycel) therapy [12,13], as well as in epithelial
growth factor receptor under gefitinib therapy [14],
and in the androgen receptor under antiandrogen
therapy [15]. In addition, amplification of gene targets
can cause resistance, and has been observed in thymi-
dylate synthase under 5-fluorouracil therapy [16], di-
hydrofolate reductase under methotrexate therapy
[17-19], and androgen receptor under antiandrogen
therapy [20]. All of these are examples of focused
searches for the cause of resistance, generally testing
the gene target of the drug. The only exception being
amplification of MET, as a downstream gene in the ep-
ithelial growth factor receptor pathway, which causes
resistance to gefitinib [21]. As of yet, there have been
Figure 1. The neoplastic cells in an allogenic stem cell transplant pa-
tient go through 3 regimes of selection. During neoplastic progression,
clones with evolutionary neutral mutations (in gray), which have no ef-
fect on survival or reproduction of the clone, expand and contract ran-
domly. Inactivation of tumor suppressor genes and activation of
oncogenes often drive clonal expansions (clones in shades of yellow,
red, and blue). Ablation introduces a new selective pressure on the neo-
plastic cells, which may kill most of them, but some clones may survive
(blue clone) and continue to generate subclones (shades of purple and
green). The allogenic immune cells then introduce a third selective re-
gime in the graft-versus-tumor reaction. If there is a clone that can es-
cape the allogenic immune response (the green clone), minimal
residual disease may remain, which can eventually lead to relapse, pos-
sibly through additional somatic evolution. Thus, relapse derives from
clones that have survived the different selective pressures of both abla-
tion and the graft-versus-tumor immune response.
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netic lesions that cause resistance to a therapy.
The fact that genetic lesions that cause resistance
have come to dominate the neoplasm at relapse shows
that the drugs have had a selective effect on the popu-
lation of self-renewing cells in the neoplasm. Thus,
therapeutic resistance is not simply a failure to kill
the CSCs. Some of them have been killed, but those
with the resistance lesions outgrew their competitors
after initiation of therapy. This is not to say that
CSCs are not harder to kill than the nonstem cells
[22]. They may be more resistant to drugs than the
nonstem cells. The evidence of genetic lesions that
cause resistance is merely evidence that there was
genetic heterogeneity within the CSC compartment,
and that the drugs have had some effect on that
compartment.
We focus on the ultimate (epi)genetic causes of
resistance rather than mRNA expression or protein
concentration changes. Changes in mRNA and pro-
teins, although directly responsible for the phenotype
of resistance, are not heritable, and so cannot be
consolidated by selection unless they derive from
epigenetic or genetic alterations. Furthermore, a single
(epi)genetic alteration can generate a large number of
expression changes in other genes, which can compli-
cate the attempt to associate any 1 gene’s expression
level change with the cause of resistance.Evolution of Relapse after Allogeneic Stem Cell
Transplantation
AlloHSCT has 2 important forms of selection on
malignant disease: ablation of the normal and
malignant cells followed by graft-versus-host (GVH)
selection (Figure 1). The malignant cells that go on
to cause relapse must initially survive ablation of the
patient’s hematopoietic system. Then, after Al-
loHSCT, they must survive the GVT reaction. Previ-
ous work on immune therapy for cancer may provide
hints as to the mechanisms that can evolve to evade
the allogeneic immune reaction [23]. These include:
(1) defects in the expression and/or function of HLA
class I antigen processing machinery components in
neoplastic cells, (2) resistance to Fas or tumor necrosis
factor-related apoptosis inducing ligand (TRAIL)-in-
duced apoptosis, (3) expression of natural killer cell
inhibitory factors, (4) induction of T and natural killer
cell apoptosis, (5) induction of T cell anergy, (6)
recruitment of T regulatory cells, and (7) induction
of abnormal differentiation of myeloid cells. Thus,
the answer to why a patient relapses must involve
answers to why it survived the initial ablation and
then why it survived the graft-versus-malignancy
reaction. These answers should form the basis of
efforts to treat patients at relapse and to develop
interventions that prevent relapse in the first place.Major Challenges Going Forward
Major challenges fall into the broad categories of
understanding the cause of therapeutic resistance after
AlloHSCT and developing better interventions to
either treat or prevent relapse.
Determine the cause of resistance
Ideally, we would sample the malignant cells that
remain shortly after ablation and compare their (epi)-
genetics to preablation malignant cells to determine
the selective effects of the ablation. Later, we could
compare these samples to the (epi)genetics of relapse
samples to determine the selective effects of graft-
versus-malignancy. Although purifying and assaying
the rare malignant cells that survive ablation is proba-
bly beyond our current technical abilities, comparing
preablation to relapse samples of the malignancy is
feasible and holds the potential to reveal the results
of both forms of selection, combined.
Develop models that recapitulate therapeutic
resistance
Preclinical models with realistic levels of (epi)ge-
netic diversity should be developed such that, when
the therapeutic intervention is applied, we are likely
to select for clones that will be resistant to the
intervention. This would help both in the discovery
of mechanisms of resistance as well as the development
of better interventions that are less prone to permit re-
lapse or can target clones that are resistant to the initial
therapy.
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Work in chronic myelogenous leukemia (CML)
shows that when we can compare pretherapy and re-
lapse disease, we can make rapid progress both in un-
derstanding the nature of resistance (eg, mutations in
BCR-ABL) and in developing agents that are still ef-
fective at relapse (eg, dasatinib) [13]. Once (epi)genetic
lesions that cause resistance have been identified, drugs
can be tested against neoplasms with those lesions to
develop either salvage therapies or combination thera-
pies, which prevent those forms of resistant clones
from flourishing in the first place.
Reduce the incidence of resistance through
combination conditioning therapy
The theory behind multidrug therapy in human
immunodeficiency virus applies to cancer as well. It
is much less likely that a mutant clone will be present
in the neoplasm that is resistant to all the drugs in
a multidrug cocktail than the chance that a clone will
be resistant to a single drug. Clinical trials have gener-
ally found that multidrug therapies work better than
single-agent therapies, but they have often only
extended life by a matter of months, and can increase
the toxicity of the therapy [24,25]. We need to
design multidrug therapies such that multiple,
independent (epi)genetic alterations are necessary to
generate resistance to the cocktail.
Slow the rate of somatic evolution to prevent
relapse
The earlier challenges are all relatively familiar,
and the CML example shows that successful strategies
can be developed. However, by measuring the evolu-
tionary dynamics that drive the process of progression
and resistance, we have the opportunity to pursue
interventions that target the evolutionary process
itself. The identification and targeting of resistance
alterations is by necessity specific to each discovered
mechanism of resistance. However, if we could slow
the rate of somatic evolution, it should slow and
perhaps even prevent relapse, regardless of the specific
lesion that causes the relapse. The rate of evolution is
determined by 4 parameters: (1) mutation rate—in this
case the rate of generation of the (epi)genetic alter-
ations that cause resistance; (2) population size—the
number of self-renewing neoplastic cells that are
evolving. The more self-renewing neoplastic cells,
the more opportunities for generating an alteration
that causes resistance; (3) generation time—the higher
the number of neoplastic cell division, the higher the
number of opportunities for generating the alterations
that cause resistance; and (4) the fitness effects of the
alterations—if a lesion that causes resistance gives
a large proliferative or survival advantage to the clone,
that clone will quickly expand in the neoplasm.Traditional approaches to cancer therapy attempt
to reduce the population size by killing neoplastic cells,
and investigators have found an inverse relationship
between the number of residual leukemic cells after
therapy and time until relapse [26-29]. If we could
reduce any of these parameters, we would slow
somatic evolution. However, it is difficult to control
a system if it cannot be measured. So an important
step toward impacting these parameters would be the
development of robust measures of the parameters of
somatic evolution.
Somatic evolution drives both neoplastic progres-
sion and some of the most difficult forms of therapeutic
resistance to treatment, including both chemotherapy
resistance and radiation resistance. This is true regard-
less of the resolution to the CSC controversy. Somatic
evolution is occurring among all the self-renewing cells
in the neoplasm, whether or not those are a minority or
a majority of the cells in a neoplasm. To understand and
prevent relapse after conditioning and AlloHSCT, we
will need to take longitudinal samples of neoplasms
to measure the selective effects of our interventions
and then develop better interventions that either
prevent or slow the evolutionary dynamics that cause
relapse.CANCER RADIATION RESISTANCE
Radiation therapy works by damaging the DNA of
cells. The damage is caused by a photon, electron, pro-
ton, neutron, or ion beam directly or indirectly ioniz-
ing the atoms that make up the DNA chain. Indirect
ionization happens as a result of the ionization of wa-
ter, forming free radicals, notably hydroxyl radicals,
which then damage the DNA. In the most common
forms of radiation therapy, most of the radiation effect
is through free radicals. Because cells have mechanisms
for repairing DNA damage, breaking the DNA on
both strands proves to be the most significant tech-
nique in modifying cell characteristics. Because cancer
cells generally are undifferentiated and stem cell-like,
they reproduce more, and have a diminished ability
to repair sublethal damage compared to most healthy
differentiated cells. The DNA damage is inherited
through cell division, accumulating damage to the can-
cer cells; as a result, cells either die or reproduce more
slowly.
The response of a cancer to radiation is described
by its radiosensitivity. Modest doses of radiation
rapidly kill highly radiosensitive cancer cells. These
include leukemias, most lymphomas, and germ cell tu-
mors. The majority of epithelial cancers is only mod-
erately radiosensitive and requires a significantly
higher dose of radiation (60-70 Gy) to achieve a radical
cure. Some types of cancer are notably radioresistant,
that is, much higher doses are required to produce
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nal cell cancer and melanoma are generally considered
to be radioresistant.
Total Body Irradiation
Total body irradiation (TBI) is used primarily as
part of the preparative regimen for AlloHSCT. As
the name implies, TBI involves irradiation of the entire
body, although in modern practice the lungs are often
partially shielded to lower the risk of radiation-
induced lung injury. TBI in the setting of AlloHSCT
serves to destroy or suppress the recipient’s immune
system, preventing immunologic rejection of trans-
planted donor stem cells. Additionally, high doses of
TBI can eradicate residual cancer cells in the trans-
plant recipient, increasing the likelihood that the
transplant will be successful.
Doses of TBI used in AlloHSCT typically range
from 10 to12 gray (Gy). At these doses, TBI both
destroys the patient’s bone marrow (BM; allowing
donor BM to engraft) and kills residual cancer cells.
Nonmyeloablative (NMA) AlloHSCT uses lower
doses of TBI, typically about 2 Gy, which do not de-
stroy the host BM, but do suppress the host immune
system sufficiently to promote donor engraftment.
In modern practice, TBI is typically fractionated.
That is, the radiation is delivered in multiple small
doses rather than 1 large dose. Early research in BM
transplantation (BMT) by E. Donnall Thomas and
colleagues [30,31] demonstrated that this process of
splitting TBI into multiple smaller doses resulted in
lower toxicity and better outcomes than delivering
a single, large dose.
Mechanisms of Radiation-Induced Cell Death in
Leukemia and Lymphoma
Apoptosis is the major form of cell death after
irradiation of leukemia and lymphoma cells. This cell
death event is a series of cascading events involving
cellular damage followed by sensing of cellular dam-
age, signal transduction and checkpoint, activation of
cell death regulatory genes and/or proteins, caspase
activation and cellular destruction, and removal of
apoptotic corpses. Although cell death can eventually
occur even when protein synthesis is blocked, the
important role of P53 and other transcription factors
in mediating apoptosis and determining tissue sensitiv-
ity to irradiation strongly argues that transcriptional
regulation is a very important in vivo mechanism in
mediating irradiation-induced cell death.
Bcl-2 and Bax were among the first group of
cell death regulatory genes identified as potential
mediators of irradiation-induced cell death. Bax is tran-
scriptionally induced by irradiation, and is often ac-
companied by a suppression of Bcl-2 expression. The
suppression of Bcl-2 and induction of Bax appears tobe dependent on P53 function. Consensus P53 binding
elements are present in the promoter region of the Bax
gene, which are required for its P53 responsiveness. In
addition to Bcl-2 and Bax, BH3-only family members
are also involved in irradiation-induced cell death.
For example, Bid is induced by irradiation in human
T cell-lineage-derived cells. Although the mammalian
and Drosophila orthologs of Ced-4/apaf-1/hac-1 were
identified only recently, it did not take long to find that
proteins in this family were also involved in irradiation-
induced cell death. Just as caspases are universally ex-
pressed, transcription of inhibitor of apoptosis (IAP)
genes has been detected in essentially all tissues. The
expression of CIAP1 in several human cancer cell lines
was significantly altered in response to ionizing irradi-
ation. Further, the expression of XIAP can be regulated
at the translation step by irradiation. Low doses of
gamma irradiation, such as those used in fractionated
TBI, increased XIAP expression through an IRES-
mediated translation mechanism, which conferred re-
sistance to irradiation-induced cytotoxicity [32,33].
The expression of both the death receptors and their
ligands, such as Fas and FasL, TRAIL, and DR5 (a
death receptor that binds to TRAIL), can be induced/
increased by irradiation and involved in irradiation-
induced cell death [34,35].Limitation of Radiation Dose Escalation to
Mitigate Resistance
Attempts to escalate the dose of TBI from 12 to
15.75 Gy resulted in a lower relapse risk, but it was off-
set by higher nonrelapse mortality (NRM) and led to no
improvement in overall survival (OS) [36,37]. These
randomized trials highlighted the difficulties in
balancing toxicity and disease control when
attempting to escalate the dose of TBI as a strategy to
improve patient outcomes. NRM may manifest at 0.7
Gy, whereas mild symptoms may be observed with
doses as low as 0.3 Gy when high-energy X-rays,
gamma rays, or neutrons are used. There are 3 classes
of acute radiation syndromes [38]. BM syndrome usu-
ally occurs with a dose between 0.7 and 10 Gy. The pri-
mary cause of death is the destruction of the BM,
resulting in infection and hemorrhage. Gastrointesti-
nal (GI) syndrome usually occurs with a dose greater
than approximately 10 Gy. Destructive and irreparable
changes in the GI tract and BM usually cause infection,
dehydration, and electrolyte imbalance. Death usually
occurs within 2 weeks without intensive therapy. Car-
diovascular and central nervous system syndrome usu-
ally occur with a dose greater than approximately 50
Gy. Death occurs within 3 days because of collapse of
the circulatory system as well as increased intracranial
pressure caused by edema, vasculitis, and meningitis.
Reduced-intensity conditioning (RIC) regimens
have drawn intensive investigation in the past decade.
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TBI (2-8 Gy). RIC regimen was feasible for patients
normally excluded from AlloHSCT by myeloablative
(MA) regimens because of older age (.50 years), re-
duced performance status, or comorbidities. Thus, se-
lection criteria for AlloHSCT could be ‘‘loosened’’ if
an RIC regimen was considered as an alternative to an
MA regimen.Targeting Stem Cell Pathway Posts Promise in
Overcoming Resistance
Tumor growth and regrowth after therapy is
a property of CSCs; their response to radiation is a crit-
ical parameter for curability. Bao et al. [39] reported
radiation resistance of CD1331 cells in glioma. This
resistance was attributed to constitutive activation of
the DNA repair checkpoint and inhibition of the
corresponding kinase radiosensitized CD1331 cells.
The observation that CSCs resist radiation has also
been reported by several groups [40]. Radiation
response curves of CSCs isolated from breast cancer
lines showed a clear radioresistance shoulder. CSCs
also failed to phosphorylate H2AX in response to radi-
ation, suggesting diminished damage or alternative
mechanisms might be involved [41].
Radiation can activate the stem cell signaling path-
way, Notch, by upregulating both the Notch ligand
Jagged-1 and downstream Hey1. The Notch pathway
is involved in stem cell maintenance in breast cancer,
and its activation by radiation increased the number
of CSCs. Activation of the Notch pathway by radiation
suggests that this pathway may contribute to the radi-
ation response of normal and malignant tissues [42].
A major obstacle to successful chemotherapy is
intrinsic or acquired multidrug resistance (MDR).
The most common cause of MDR involves increased
drug efflux from cancer cells mediated by members
of the ATP-binding cassette (ABC) transporter family
[43]. The regulation of ABC transporters in the con-
text of cancer is poorly understood, and clinical efforts
to inhibit their function have not been fruitful. Sims-
Mourtada et al. [44,45] showed that inhibition of
hedgehog (Hh) signaling increases the response of
cancer cells to multiple structurally unrelated
chemotherapies. Hh pathway activation induces
chemoresistance in part by increasing drug efflux in
an ABC transporter-dependent manner. Hh signaling
regulates the expression of the ABC transporter
proteins multidrug resistance protein-1 (MDR1,
ABCB1, P-glycoprotein), the breast cancer resistance
protein (BCRP), and the ATP-binding cassette
(ABCG2), and that targeted knockdown of MDR1
and BCRP expression by small interfering RNA
partially reverses Hh-induced chemoresistance [44].
Similarly, Chen et al. [46] showed that downregulation
of Hh signaling with an inhibitor, cyclopamine,improved tumor control in vivo without increased
toxicity.
Diffuse large B-cell lymphoma (DLBCL) expresses
sonic Hh more frequently and more intensely than fol-
licular lymphomas or chronic lymphocytic leukemia
(CLL)/small lymphocytic lymphoma. Dysregulation
of Hh signaling pathway was shown in DLBCL. Kim
et al. [47] assessed 67 cases of DLBCL for expression
of Hh ligand, GLI1, GLI2, and GLI3 (transcriptional
effectors of Hh signaling), and ABCG2. In DLBCL,
these Hh markers were expressed in 72% to 91% of
cases, and more importantly, expression of ABCG2
was detected in 95% of patients. Patients with DLBCL
with high ABCG2 expression showed significantly
shorter OS compared with patients with tumors with
low or no expression of ABCG2. Hh signaling was
positively correlated with expression levels of
ABCG2; this association implies likely involvement of
Hh in chemoresistance of lymphomas [47].
B cell CLL (B-CLL) is characterized by an accu-
mulation of neoplastic B cells because of their resis-
tance to apoptosis and increased survival. Among
various factors, the tumor microenvironment is known
to play a role in the regulation of cell proliferation and
survival of many cancers. However, it remains unclear
how the tumor microenvironment contributes to the
increased survival of B-CLL cells. Hegde et al. [48]
studied the influence of BM stromal cell-induced Hh
signaling on the survival of B-CLL cells, and showed
that Hh signaling inhibitor, cyclopamine, inhibits
BM stromal cell-induced survival of B-CLL cells, sug-
gesting a role for Hh signaling in the survival of B-
CLL cells. Furthermore, selective downregulation of
GLI1 by antisense oligodeoxynucleotides (GLI1-
ASO) results in decreased BCL2 expression and cell
survival, suggesting that GLI1 may regulate BCL2
and, thereby, modulate cell survival in B-CLL. These
results suggest that overexpression of the stem cell
pathways is associated with aggressive subsets of leuke-
mia and lymphoma, and downregulation of these stem
cell signaling pathways posts promise in overcoming
resistance to chemotherapy and radiotherapy without
increasing NRM.RESISTANT LEUKEMIC STEM CELLS
Over the past decade, experimental evidence de-
scribing the existence and properties of human leuke-
mic stem cells (LSCs) has become substantial. Using
advanced experimental systems, investigators have de-
scribed multiple aspects of LSC biology. Such features
include cell surface immunophenotype, cell cycle status,
gene expression profiles, signal transduction pathways,
and drug sensitivities [49-58]. Thus, the general
characterization of LSCs has made considerable
progress. However, the role of LSCs in the overall
Figure 2. Proposed model of the developmental hierarchy in the development of acute myelogenous leukemia, similar to normal hematopoiesis.
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to disease relapse, remains poorly understood. Indeed,
the degree to which LSCs are successfully targeted
and their relative contribution to relapse after
AlloHSCT has not been directly measured in
leukemia patients. Hence, although the concept of an
LSC provides an appealing explanation for the
responses typically observed in patients undergoing
conventional therapy, it remains to be determined
whether more effective targeting of LSCs will provide
superior clinical outcomes after AlloHSCT.
Evidence for a central role of human LSCs comes
mainly from analysis of primary human acute leukemia
specimens transplanted into immune deficient mice
[59]. Studies of this nature have shown that for acute
myelogenous leukemia (AML), subpopulations of cells
can be identified that possess the ability (or lack
thereof) to drive engraftment and growth in xenografts
[49,57,60,61]. Furthermore, cells with the ability to
mediate engraftment of immune-deficient mice
express specific patterns of cell surface markers, which
at least partially overlap with those found on normal
hematopoietic stem and progenitor cells. Taken
together, such studies have established that AML spec-
imens are organized in a developmental hierarchy
analogous to that found in normal hematopoiesis
(Figure 2). These findings have been further corrobo-
rated by the development of syngeneic mouse leuke-
mia models, in which defined LSCs can also be
identified [62-64].
Despite the studies noted before, there have also
been reports that appear to contradict the concept of
an LSC in some cases. These observations have been
most prevalent for acute lymphoblastic leukemia(ALL), where reports differ substantially, with some
groups arguing that there is no consistent phenotype
for candidate ALL stem cells, whereas others do ob-
serve defined characteristics and phenotype [65-67].
Thus, although evidence for LSC is considerable, it
appears likely that specific properties of LSCs (ie,
phenotype, frequency, drug resistance, etc.) may vary
as a function of parameters such as disease type,
genetics, and cell type.
Importantly, failure to eradicate the LSC popula-
tion is also clearly implicated as a major factor in
leukemic relapse following AlloHSCT. Relapse in
this context implies that some LSCs are not only
resistant to chemotherapy, but are also insensitive to
the immunologic reactivity induced by graft-versus-
leukemia (GVL) effects. If true, then it may be of sub-
stantial interest to consider graft engineering strategies
that would enhance anti-LSC immunity. Notably, 1 re-
port has specifically addressed this issue and indicated
that in at least some cases LSCs do express minor
histocompatibility antigens and can be killed by T cells
reactive against them [68].Evidence for Drug Resistant LSC
Given the issues outlined earlier, several studies
have attempted to better understand the relative drug
resistance/sensitivity of primitive AML cells. For
example, Guzman et al. [52] demonstrated that
cytarabine treatment of primary AML cells in vitro
demonstrated marked differential sensitivity. Although
bulk tumor cells showed a relatively strong cytotoxic
response to drug treatment, a small population of
phenotypically primitive cells was substantially less
Table 1. Agents That Eradicate Leukemic Stem Cells While
Sparing Hematopoietic Stem Cells
Small molecule-based regimens
MG132 + Idarubicin [148]
LY294002 + etoposide [149]
Parthenolide (PTL) [150]
Dimethylamino parthenolide (DMAPT) [151]
TDZD-8 [152]
Celastrol [153]
4-Hydroxynonenal (4-HNE) [153]
ABT-737 [154]
Biologic regimens
DT-IL3 [155]
Anti-CD44 [156]
Anti-CD123 [157]
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that phenotypically primitive AML cells were almost
entirely quiescent, a physiological property commonly
associated with normal hematopoietic stem cells
(HSC) [50]. Given the well-known preferential activity
of cytarabine for actively cycling cells, this observation
provides at least 1 explanation for the differential drug
sensitivity of AML cell populations that may possess
differing degrees of drug sensitivity. A study from
Costello et al. [69] provided similar results for the treat-
ment of LSCs with anthracyclines in vitro. This report
showed that primary AML cells expressing a primitive
cell surface phenotype (CD341/CD38-) were less sen-
sitive to daunorubicin than bulk leukemia cells. Finally,
a recent manuscript by Ishikawa et al. [70] described an
elegant study in which immune-deficient mice bearing
primary human AML xenografts were challenged with
cytarabine. Notably, in vivo eradication of AML cells
was relatively efficient for overall tumor, but markedly
less effective for the more primitive subpopulation.
Taken together, these studies appear to firmly support
the concept that AML populations possess a significant
degree of heterogeneity with regard to drug response,
and that cells associated with a primitive phenotype
are more resistant to commonly used leukemia drugs.
Thus, commonly used leukemia drugs should select
for an increased frequency of AML cells with a primitive
phenotype among the surviving AML cells.
Aside from the drug studies outlined before, the
other major line of investigation on the role of LSCs
has come from Schuurhuis and colleagues [71-73],
who have performed detailed analyses of candidate
LSC populations in patients undergoing
chemotherapy treatment and AlloHSCT. These
studies have demonstrated that the presence and
frequency of phenotypically primitive AML cells
directly correlates with patient prognosis and clinical
outcome.Current and Emerging Therapies
As noted before, several studies have indicated that
conventional agents may not effectively eradicate the
LSC population in AML. However, with a plethora
of new agents in varying stages of analysis, it is possible
that alternative approaches may prove efficacious. Un-
fortunately, to date, very few drugs have been validated
with regard to selective targeting of LSC. Indeed, this
is typically not a criterion in the development of leuke-
mia drugs. Thus, although many intriguing new agents
are available, their relative efficacy toward LSC is
largely unknown. Table 1 shows the published agents
that have shown the ability to target primary human
AML LSC, while also sparing normal hematopoietic
stem and progenitor cells.
In addition to the reports summarized in Table 1,
there have also been some exciting studies in murinemodels that demonstrate selective targeting of LSC
for specific subtypes of myelogenous leukemia (eg, leu-
kemia models driven by BCR/ABL and promyelocytic
leukemia–retinoic acid receptor alpha PML-RARa
translocations) [74-76]. These approaches have used
novel combinations of conventional agents, as well as
new drugs that target pathways implicated in self-
renewal of LSCs.Major Challenges Going Forward
To develop more effective strategies for eradication
of LSCs, there are several important objectives the
research community must address.
Preclinical models
There are currently no preclinical models for eval-
uation of therapeutic regimens that have demonstrated
to be predictive of therapeutic efficacy in patients. Al-
though numerous reports have described relatively so-
phisticated xenograft models using primary human
leukemia specimens in immune-deficient mice, it is
not yet clear whether such systems can be used to reli-
ably assess LSC targeting for patients.
Allogeneic BMT models
With the development of good systems to study
primary murine and human LSCs, it should be possible
to examine therapeutic strategies specifically in the
context of a post allogeneic BMT setting. Indeed, by
modeling how LSCs react to BMT, and studying
reemergence of disease driven by resistant-LSCs, it
may be possible to devise intriguing new strategies
that employ both chemotherapy and immunologic
components to achieve superior outcomes.
MRD models
One scenario in which candidate anti-LSC drugs
are potentially useful is for consolidation or mainte-
nance therapy following conventional AML treatment.
Particularly for patients achieving complete remission,
the concept of drugs that may suppress or eradicate
residual disease is clearly appealing. However, as yet,
Figure 3. Proposed model of progression from committed hematopoietic stem cell progenitor cells transformed by an oncogene MLL-AF9 into a leu-
kemia stem cell (LSC).
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effectively studied. This is a potentially important is-
sue, because evidence suggests that leukemia cells in
an MRD state may behave differently than cells
present during conditions of heavy disease burden
[77]. If true, then drugs developed using current
models may or may not be effective toward cells
present in MRD.Clinical endpoints
The conventional clinical endpoints currently
employed to assess the success of therapeutic agents
in leukemia is clearly inadequate for analysis of
LSCs. A key point for future studies will be the need
to incorporate more sophisticated correlative studies
and more comprehensive pharmacodynamic measures
to assess relative efficacy toward LSC [78].
Progress over the past decade has provided several
exciting new options for the development of improved
leukemia therapy. Investigators have described many
aspects of LSC biology, including physical features,
gene expression and signal transduction aberrancies,
and developmental properties. Nonetheless, a variety
of challenges remain in terms of making these findings
meaningful for leukemia patients post-AlloHSCT. In-
deed, the translation of such data is hampered by the
lack of validated preclinical models, conventional clin-
ical endpoints that do not adequately reflect targeting
of LSCs and a lack of understanding of the (epi)genetic
heterogeneity within the evolving LSC population.
Thus, it will be critical in the near term to develop
more sophisticated clinical paradigms, which will serveto help validate preclinical models and more directly
demonstrate the relevance of targeting LSC.GENOMIC BASIS OF LEUKEMIC RELAPSE:
TARGETING SELF-RENEWAL PATHWAYS IN
LEUKEMIA
Related issues at the center of studies focused on
CSC development include the cells of origin and the
molecular phenotype of fully developed CSCs. Murine
models of leukemia demonstrate that immature
hematopoietic populations enriched for HSC are quite
permissive for leukemic transformation, and that more
differentiated myeloid progenitor cells are more
restricted in their transformation potential [79].
However, these committed progenitor cells can be
directly transformed by oncogenes such as MLL-
AF9 and MOZ-TIF2 (Figure 3) [58,80]. This direct
transformation of differentiating progenitor cells is
important not only because it provides an
experimental system to study the process of LSC
development, but also because the phenotype of
LSCs in multiple models of AML is most consistent
with differentiating cells at a midmyeloid stage of
development [58,64,80-82]. Therefore, it appears, at
least in model systems, that a major mechanism by
which AML develops is the acquisition of self-
renewal properties in cells that do not normally have
this ability independent of whether this is activated
de novo, as in the case of direct transformation of
progenitors, or whether this property is maintained
718 Biol Blood Marrow Transplant 16:709-728, 2010M. S. Cairo et al.during differentiation from an HSC to nonself-
renewing progenitor cells.
The transition of self-renewal properties from
stem to progenitor cell populations during AML
development raises the question as to what pathways
are uniquely active in HSC that make them prime
candidates for leukemic transformation, and are these
pathways required for initiation and/or maintenance
of self-renewal in more differentiated cells. A related
critical question is whether CSCs possess a greater
dependence on specific developmental/self-renewal
pathways than do normal stem cells. If so, these path-
ways become potential therapeutic targets for CSCs.
Examples of such pathways that are emerging as
potential therapeutic targets in multiple diseases are
discussed in the following section.The Wnt/b-Catenin Pathway
The canonical Wnt signaling pathway has
emerged as a critical regulator of HSC development
[75,83-85]. Studies that have inactivated b-catenin
during either mouse or zebrafish development
demonstrate an important role for this pathway
during developmental specification and expansion of
HSC. However, experiments designed to assess the
continued requirement of b-catenin for adult HSC
show that it is not absolutely required for their
maintenance [75,86,87]. This finding suggests that
the Wnt/b-catenin pathway may be important for
supporting stem cells during specific types of
environmental stress or perhaps states, like
development, which require significant stem cell
expansion [85,88,89]. The less stringent requirement
for b-catenin activity in adult HSC prompts the
question as to the necessity of the Wnt/b-catenin
pathway for CSC self-renewal. Aberrant activation of
the Wnt pathway is implicated in various human can-
cers, including blast crisis CML [90], skin [91], and co-
lorectal cancers [92-94]. Previous studies have
demonstrated the potential for activated b-catenin in
AML cells, but functional demonstration of the
importance of this pathway in AML is lacking
[95,96]. However, recent genetic studies do indicate
a role for b-catenin in a model of a BCR-ABL driven
myeloproliferative disease similar to chronic phase
CML [75]. In this model, as in human chronic phase
CML, the LSC has immunophenotypic and functional
properties similar to normal HSC. This is quite differ-
ent from multiple models of murine AML where LSC
have an immunophenotype and gene expression pro-
file more similar to differentiating myeloid progenitor
cells. Therefore, studies are needed to address the im-
portance of this pathway for hematologic malignancies
where the therapeutically relevant cell type is similar to
a more differentiated hematopoietic cell.The demonstration that the b-catenin pathway is
important for CML development in a well-defined
model system is an important first step toward demon-
strating the possibility that this pathway may be
considered a therapeutic target in leukemia. However,
given that CML stem cells are quite similar to normal
HSC, data are still needed to support the concept that
this pathway is important for other hematopoietic ma-
lignancies. This is particularly important given recent
publications demonstrating the potential to develop
small molecule inhibitors of the Wnt/b-catenin path-
way [97]. As noted before, normal HSC do not have
a strict requirement for b-catenin to survive. There-
fore, therapeutics that disrupt b-catenin signaling
may have a greater effect on leukemia and perhaps
other CSCs than normal stem cells. Determining the
therapeutic efficacy of small molecule pathway inhibi-
tors against leukemias, and therapeutic index for
leukemia efficacy versus toxicity toward normal stem
cell populations, and functional heterogeneity among
leukemic cells for dependence on b-catenin signaling,
will be of critical importance for developing novel
therapies targeting this pathway. Continued develop-
ment of sophisticated model systems including
genetically engineered mouse models and even more
sophisticated systems that assess human leukemia
development and survival in mice will be critical tools
for assessment [98,99].The Hh Pathway
The Hh pathway, similar to the Wnt/b-catenin
pathway, may have a role in certain CSCs [76,100,101],
and initial studies suggest that the Hh pathway may be
active in some human acute leukemias. However, this
pathway has been most extensively studied in subsets of
pediatric medulloblastomas because of the association
between germline mutations in PTCH1, a critical
component of the Hh pathway, and the development
of medulloblastomas and basal cell carcinomas [102-
104]. The Hh pathway clearly plays an important role
in medulloblastomas, as recent therapeutic clinical
trials have demonstrated activity of a Hh pathway
antagonist against human medulloblastomas [105]. Re-
cent data have begun to address the role for the Hh path-
way in normal and malignant hematopoiesis. As is the
case with the b-catenin pathway just described, experi-
mental results in model systems have been somewhat dif-
ferent, dependent on the developmental stage at which
the pathway is inactivated. If inactivated during fetal de-
velopment in the hematopoietic system, adult HSCs ap-
pear to be compromised. However, if the Hh pathway is
inactivated in fully developed HSCs there appears to be
a less dramatic requirement at least as assessed by inacti-
vation of the critical signaling molecule, smoothened
[76,106,107]. Thus, it appears at least plausible that
therapeutics that target this pathway might not suffer
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studies assessing this pathway in an experimental model
of AML show that it was not required for leukemia
initiation [107]. Therefore, more studies are required
to determine if this pathway is crucial for certain subsets
of acute leukemias.
Histone Methylation
Histone methylation is increasingly recognized as
a major mechanism for the control of gene expression,
and recent data suggest that the enzymes that modify
histones such as EZH2 (H3K27 methylation) and
DOT1L (H3K79 methylation) may be playing a direct
role in the oncogenic mechanism of leukemia associ-
ated fusion proteins such as mixed lineage leukemia
gene (MLL)-fusions and PML-RAR. A number of
proteins found fused to MLL have been shown to
interact with a histone methyltransferase, DOT1L
[108,109]. DOT1L modifies histone H3 on lysine
79, a modification associated with enhanced gene
expression and cell cycle progression [108,110]. This
finding has led to the hypothesis that histone
methylation MLL-fusion proteins drive gene expres-
sion at least in part by aberrant recruitment of histone
modifying activity to MLL target genes. Although the
study of this modification and its importance in normal
and leukemic transcription is just beginning, further
study of DOT1L as a potential therapeutic target in
MLL fusion leukemias is warranted. A second example
of a histone modifying enzyme as potentially relevant
in leukemia is the recent demonstration that the histone
H3 lysine 27 methyltransferase EZH2 is a component of
PML-RAR complexes and may be critical for the devel-
opment of acute promyelocytic leukemia [111]. Finally,
a third example of histone modifying activity as poten-
tially relevant in leukemia is the identification of the in-
teraction between the leukemogenic oncoprotein EVI-1
and the histone methyltransferase gene G9A [112,113].
It is expected that the continued characterization of the
role of histone modifications in the control of gene
expression will lead to an increasing number of
potential therapeutic targets against which small
molecules can be developed. As these enzymes are
likely to control programs of gene expression, they
represent attractive therapeutic targets that might be
exploited to reverse aberrant gene expression in
leukemia. However, a critical component of this line
of research will be to determine the extent to which
these enzymes can be targeted for reversal of
leukemogenic programs without significant toxicity to
normal stem and progenitor cells, and the likelihood
that resistant subclones grow out in response to therapy.
Biomarkers of Pathway Activation
The pathways described before, which represent
potential new therapeutic opportunities, and smallmolecule inhibitors that disrupt the b-catenin path-
way, Hh pathway, and histone methylation, are being
developed. Early studies in model systems suggest
that these pathways will play an important role in cer-
tain subsets of leukemia. A critical component of fu-
ture development of these inhibitors as therapeutics
will rely on the ability to determine if a given leukemia
demonstrates activation of these pathways and the ex-
tent of heterogeneity of activation of those pathways
among the leukemic cells. Following the paradigm
set by kinase inhibitor treatment in leukemia, if there
is a reliable genetic test that guides therapy, connect-
ing the appropriate inhibitor with the appropriate leu-
kemia is significantly easier. However, to date, genetic
mutations in members of these pathways have not been
found to be particularly frequent. It appears that leuke-
mogenic fusion oncoproteins and other unknown
mechanisms lead to pathway activation. Therefore,
continued characterization of the mechanisms by
which these pathways are activated in leukemia, and
the mechanisms of therapeutic resistance, both
through the use of detailed model systems and
genome-wide approaches in human leukemias, will
hopefully lead to the identification of recurrent abnor-
malities that can be used to predict sensitivity and
response to specific therapeutics. The development
of biomarkers will be critical for the rapid translation
of inhibitors of these pathways into clinical medicine.
Developmental pathways that are classically de-
scribed as being involved in stem cell self-renewal
such as those described represent a potential new op-
portunity for intervention in leukemia. The optimism
for development of targeted therapeutics against these
pathways is heightened by recent demonstration that
small molecule inhibitors can be developed. Moving
forward, it will be critical for the scientific community
to develop a detailed understanding of the mechanisms
by which self-renewal pathways are activated in human
leukemias, and therefore can be targeted therapeuti-
cally. Although there is much work to be done, early
studies suggest that targeting self renewal in leukemia
may have significant therapeutic value.CANCER EPIGENETICS: THERAPEUTIC
REPROGRAMMING OF LYMPHOMA AND
LEUKEMIA CELLS
Transcription Factors and Cofactors are
Potential Therapeutic Targets in Cancer
Aberrant transcriptional programming is a hallmark
of cancer, and is the result of deregulated transcription
factors and chromatin modifying complexes. Because
these proteins can regulate hundreds or even thousands
of genes, they have the potential to affect numerous
biological pathways. Given this fact, it is not surprising
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transcriptional regulators (ie, p53, Rb, MYC, Notch,
BCL6, etc.). Some of these are transcription factors,
which have DNA binding domains that recognize
specific genomic elements but usually have no catalytic
activity. Others are cofactors with enzymatic and struc-
tural functions, which form multifunctional complexes
that introduce chemical modifications of DNA,
histones (as discussed above) and other proteins. Tran-
scription factors confer specificity to chromatin modi-
fying complexes by directing them to specific regions
of the genome. Key biologic pathways tend to feature
binding of a given transcription factor to many genes.
Functionally related genes can thus be controlled
through a common biochemical mechanism [114].
For example, the B-cell lymphoma 6 (BCL6) transcrip-
tional repressor binds to multiple genes in a DNA
damage-sensing pathway including the ATR, CHEK1,
TP53, CDKN1A, and GADD45A genes [115]. It also
appears that the genomic distribution of transcription
factor binding is different in cancer versus normal cells
[116]. Tumor-specific binding patterns presumably fa-
cilitate regulation of genes required to maintain the
malignant phenotype. Collectively, these features
make transcription factors excellent targets for the
therapeutic reprogramming of tumor cells.
Transcription factor inhibitors would be expected
to be highly specific in their actions, in that they would
only affect limited and specific sets of target genes di-
rectly related to tumor pathogenesis, and, by the same
token, would be expected to have a wide therapeutic
window. By inhibiting protein interactions between
transcription factors and cofactor complexes, it would
be theoretically possible to regain control of key
downstream oncogenic pathways. However, protein-
protein interactions often involve large interfaces
with multiple intermolecular contacts mediated by
many amino acid side chains. These features present
a challenge for the design and development of small
molecule inhibitors, which are generally believed to
inefficiently disrupt such large surfaces [117]. Protein
interactions have thus been traditionally viewed as
‘‘undruggable.’’ However, recent advances in struc-
tural biology, computer-aided drug design, and bio-
chemistry may overcome some of these limitations
[117]. In contrast, transcriptional cofactors are gener-
ally viewed as more tractable therapeutic targets. Many
of these proteins mediate their actions through enzy-
matic reactions, and enzymatic pockets are more easily
occluded by small molecules [117]. Transcriptional
cofactors interact with many different transcription
factors. Therefore, the number of genes that could
be affected by inhibitors of these proteins is potentially
much greater, and may lead to undesired effects. Many
of these proteins are also active in other biologic
processes beyond transcription. Drugs that target
transcriptional cofactors may thus be expected toexhibit pleiotropic effects and a narrower therapeutic
window than transcription factor inhibitors.
Transcriptional complexes mediate their actions by
altering the chemical composition of chromatin, a pro-
cess that involves methylation of CpG dinucleotides,
the reversible addition or subtraction of chemical mod-
ifications to histones, and the movement, disruption, or
remodeling of nucleosomes and other chromatin asso-
ciated proteins [118,119]. These modifications result in
the creation of complex 3-dimensional structural
configurations that determine transcription rate, exon
use, tissue specificity, availability of genes to be
expressed in response to signaling pathways, etc. The
information contained within these chromatin
configurations is often referred to as ‘‘epigenetic’’
programming, because it is beyond the information
contained in the genetic code. It is apparent that
certain epigenetic marks or combinations are stably
transmitted as cells divide and differentiate; that is,
they are heritable and thus a substrate for natural
selection [118,119]. Stable modifications can transmit
important transcriptional programming information
even in the absence of the transcription factor that
may have initially written in these instructions.
These transcriptional control mechanisms are of
particular importance in normal and malignant stem
cell biology. Specific transcription factors, some of
them bona fide oncogenes, can reprogram somatic cells
into induced pluripotent stem (iPS) cells [120], or can
reprogram terminally differentiated hematopoietic
lineage into another (ie, from T cell or B cell to macro-
phage, for example) [121]. LSCs display significantly
different transcriptional programming than normal
HSC [122]. Identification of the transcriptional and
epigenetic mechanisms that mediate the malignant
programming of LSCs could provide the basis for
design of stem reprogramming therapy to eradicate
MRD and prevent relapse.Evidence That Transcriptional Reprogramming
Can Be an Effective Therapy
Several lines of evidence support the notion of tran-
scriptional reprogramming as an effective therapeutic
strategy. The paradigm for transcription therapy was
provided by the serendipitous discovery of the ability
of retinoids to powerfully induce differentiation in
acute promyelocytic leukemia (APL) cells harboring
the t(15;17) translocation [123]. The PML-RAR fusion
protein resulting from this translocation can aberrantly
repress RARa target genes as well as bind to novel genes
not normally regulated by this factor [123]. The engi-
neered expression of PML-RAR in mice induces a he-
matologic disorder that mimics many of the features of
human APL. The retinoid, all-trans-retinoic acid
(ATRA), can overcome the aberrant transcriptional ac-
tions of PML-RAR and reprogram leukemia cells to
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of patients with APL, with few toxic side effects [123].
Outside of APL, there is little therapeutic activity for
ATRA. These effects are consistent with the prediction
that drugs directly targeting transcription factors
would have potent antitumor effects and a wide thera-
peutic window. The fact that most tumors are driven by
more than 1 oncogenic lesion, and therapies select for
resistant subclones, is underlined by the fact that pa-
tients with APL eventually relapse after ATRA therapy
and require combinatorial therapy with chemotherapy
or other drugs for definitive eradication of the disease
[124]. The success of ATRA therapy led to the notion
that drugs that could disrupt other key transcription
factors might be equally effective in other tumor types.
ATRA mimics the binding of a natural ligand for
RARa, a protein that has evolved to alter its conforma-
tion and function in the presence of these compounds.
The challenge is greater when trying to design inhibi-
tors for transcription factors that do not have known
natural chemical ligands. For example, the BCL6 tran-
scriptional repressor is the most frequently involved
oncogene in B cell lymphomas, and may also contrib-
ute to other tumors [115]. BCL6 is especially linked to
the pathogenesis of DLBCL, which is the most com-
mon type of non-Hodgkin lymphoma. Constitutive
expression of BCL6 in mice results in the formation
of DLBCL-like tumors in mice, and BCL6 is thus
believed to be a critical therapeutic target [125].
From the biochemical standpoint BCL6 is a member
of the BTB-zinc finger family of transcription factors.
The BCL6 BTB domain has autonomous repressor
activity, which is dependent on the recruitment of 3
corepressor proteins called silencing mediator of reti-
noid and thyroid nuclear hormone receptors (SMRT),
nuclear hormone receptor corepressor (N-CoR), and
BCL6 corepressor (BCoR) [126]. From the structural
standpoint the BCL6 BTB domain forms an obligate
homodimer [127]. An 18-residue peptide from the
corepressor partner proteins runs through a groove
formed between the 2 BTB monomers, making exten-
sive intermolecular contacts with residues from both
monomers [127]. Peptides that mimic the 18-residue
corepressor BCL6 binding peptide can block the for-
mation of BCL6 transcriptional repression complexes
and derepress BCL6 target genes [128].
To create a therapeutically useful inhibitor that
could penetrate tumor cells and block the actions of
BCL6, peptidomimetic inhibitors were generated
using the pTAT protein transduction domain [129].
This strategy bypasses the limitations of small mole-
cules in disrupting large protein interfaces by deliver-
ing much larger peptides into cell nuclei, where they
can bind to the surface of their target and block its pro-
tein interactions. BCL6 peptidomimetic inhibitors
potently killed DLBCL cells in vitro and in vivo, and
were nontoxic to normal tissues [129]. Sophisticatedcomputational algorithms allow interfaces such as
that of BCL6 to be more accurately modeled for the
presence of potential protein interaction hot spots, to
which small molecule inhibitors might bind and mimic
the actions of larger peptides [130]. Initial reports
show that it is feasible to generate small molecule
inhibitors that can disrupt the protein interactions of
leukemogenic transcription factors [131,132]. Drugs
targeting critical tumor initiation and maintenance
transcription factors such as BCL6 could potentially
help to eradicate tumor repopulating stem cells,
especially when aberrant transcriptional or epigenetic
programming requires the continued presence of an
oncogenic transcription factor.
In addition to being induced by oncogenic tran-
scription factors, aberrant epigenetic/transcriptional
programming may also occur in cells during the
normal aging process, because of environmental causes
or in accelerated cell turnover states such as inflamma-
tory syndromes [118]. In these cases, tumor initiating
and repopulating cells may acquire a critical mass of
epigenetic lesions that contribute to tumorigenesis
even without a driving transcription factor. In other
cases, lesions may occur in general epigenetic machin-
ery components. For example, it was recently shown
that the TET2 gene is mutated in patients with various
myeloid malignancies [133]. Because the TET2 family
member TET1 has been shown to have a role in modi-
fying methylcytosine, it is conceivable that loss of TET2
might alter the distribution of methylcytosine through-
out the genome. Other components of the epigenetic
machinery such as the histone methyltransferase
EZH2, which mediates epigenetic silencing through
trimethylation of histone 3 lysine 27, has been shown
to be highly expressed and contribute to prostate cancer
[134], and the Polycomb PRC1 complex protein Bmi-1
is amplified in B cell lymphomas [135].
Because epigenetic programming is essential for
establishment of normal cellular phenotypes and
presumably the malignant phenotype as well, it is not
unreasonable to expect epigenetic therapy drugs to
be impactful. Epigenetic targeted therapy with DNA
methyltransferase inhibitors (MTIs) and histone
deacetylase inhibitors (HDIs) has proven therapeutic
efficacy in myelodysplastic syndromes (MDS) in the
case of the former [136] and cutaneous T cell lympho-
mas in the case of the latter [137]. DNA methylation
mediates gene silencing in part through recruitment
of methyl-binding domain (MBD) and Kaiso family
proteins, both of which in turn recruit HDACs
[138]. Accordingly, the combination of MTI and
HDI can synergistically induce gene expression and
killing of malignant cells [139]. In early-phase clinical
trials the combination of MTI and HDI seems to ben-
efit patients with MDS [140]. In other tumor types, the
clinical effects of these drugs have generally been mod-
est. However, it is possible that suboptimal dose
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potential of these drugs. Another major issue pertains
to the many nonepigenetic off target effects of MTIs
and HDIs, some of which may be counterproductive.
Still another barrier toward successful epigenetic ther-
apy is the relative lack of understanding of how the var-
ious marks cooperate to regulate gene expression at
a global level. Under certain circumstances, for exam-
ple, histone modifications may precede and direct
DNA methylation [141]. It might be necessary to tar-
get additional components of the epigenetic regulatory
machinery such as histone methyltransferases, etc., to
fully realize the potential of this approach.Major Challenges Going Forward
Identify the patterning and biologic impact of
aberrant epigenetic programming in leukemias and
associated disorders
The various levels of epigenetic programming are
likely to play a fundamental role in determining the phe-
notype of LSCs and thus the clinical course of the disease.
Emerging evidence suggests that epigenetic lesions are
widespread in leukemias [142,143]; whereas at least in
leukemia with normal cytogenetics there is a paucity of
genetic lesions. Moreover, integrative analysis of DNA
methylation, histone modification, and gene expression
profiles could synergize in capturing differential gene
regulation between leukemia patients [144]. Future stud-
ies should attempt to decode tumor cell epigenomics to
generate models that explain how the cellular phenotype
is controlled and evolves, and thereby provide a rational
basis for selecting patients for specific epigenetic therapy
approaches.
Determine whether epigenetic signatures are
predictive of MRD persistence
It is reasonable to explore the contribution of epi-
genomic patterning to leukemic cell survival of ther-
apy, MRD persistence, and silencing of tumor-related
antigens that have an impact on immune clearance of
residual tumor cells. Many epigenetic marks are by def-
inition transmitted from stem cells to bulk tumor cells,
as has been formally demonstrated in MDS [143].
Therefore, it is feasible to explore epigenomic signa-
tures even in patient samples for which stem cell
fractions are not available. Epigenomic signatures
that indicate the existence of therapy-resistant stem
cells would provide a rationale for use of epigenetic
therapy for stem cell reprogramming and eradication.
Identify the optimal therapeutic targets for
epigenetic therapy
Major efforts are underway to design inhibitors of
the various epigenetic modifiers, and there are poten-
tially thousands of such proteins with relevance tocancer. Because epigenetic patterns vary widely in
cells, it is likely that different components of the epige-
netic machinery contribute more specifically to certain
tumors than others. It is not sufficient to screen
a generic cell line for dependency or ‘‘addiction’’ to
a specific epigenetic enzyme or complex. For example,
certain cohorts of AML patients display predominant
DNA hypermethylation, whereas others display
predominant hypomethylation of promoters [142].
Therapeutic targeting should be performed in the
context of which epigenetic marks are dominantly
disturbed, and should measure the likelihood with
which therapeutic resistance evolves.
Identify and target master regulatory
transcription factors
Abnormal epigenetic gene regulation may be
a direct consequence of an aberrantly expressed or func-
tioning transcription factor. Several such factors are rou-
tinely analyzed in the course of diagnostic staging, such
as BCL6, PML-RAR, and AML1-ETO. Others, such as
IRF4, FOXP1, and CEBPA, are also frequently queried.
The ‘‘footprint’’ of key transcription factors can be oth-
erwise inferred based on their target genes being prefer-
entially epigenetically modified. As proof of principle,
a recent study showed that AML cases with aberrant
EVI1 expression (which have a very poor prognosis), dis-
play a unique hypermethylation signature. The hyper-
methylated genes were observed to contain EVI1
consensus binding sites, and loss of EVI1 resulted in
loss of methylation of these genes [145]. Presumably,
therapeutic targeting of EVI1 could specifically erase
aberrant DNA methylation in these types of AML cells.
It is important to continue to identify such factors and
study their biochemical mechanisms of action to design
specific inhibitors.Optimize epigenetic reprogramming drug
schedules
Timing is critical in considering the proper clinical
implementation of epigenetic therapy. Because there is
a functional interrelationship between the various
epigenetic marks, and the disposition of epigenetic
marks is also dependent on other cellular processes
such as cell cycle and proliferation, it will be essential
to consider the dose, duration of exposure to each
drug, the timing and order in which they are adminis-
tered, etc. In the case of MTIs, several cell divisions
must be completed for DNA methylation to be de-
pleted, and the gradual reduction in methylation leads
to loss of binding sites for methylation dependent re-
pressor proteins, with consequent effects on histone
modifications, and vice versa. Given this complex ki-
netics, and the potential for tumor architecture and
microenvironment to contribute to transcriptional
programming of tumor cells, it is critical to compare
Figure 4. Proposedmodel of the balance of genetic and epigenetic con-
tent in the progression of tumor stem cells to a malignant phenotype.
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retical and animal models.
Rigorously explore off-target effects of
epigenetic therapy drugs
Both the MTIs and HDIs have significant off-target
effects beyond their actions on DNA methylation and
histone acetylation. MTIs and HDIs can both induce
DNA damage responses [146,147], and HDIs affect
the acetylation of hundreds of other proteins in
addition to histones [137]. It is still not known whether
the epigenetic effects of these drugs are the main factors
contributing to their antitumor effects. Being cognizant
that many of the chromatin modifying enzymes have
other actions beyond transcriptional control is key for
the rational deployment of these drugs for the therapeu-
tic targeting of MRD and tumor stem cells.
The great diversity of phenotypes that human cells
can adopt in normal tissues is dependent on the proper
patterning of epigenetic marks throughout the genome.
A growing body of evidence suggests that the malignant
phenotype is just as dependent on epigenetic program-
ming as normal phenotypes, although it is clear that
genetic lesions may initiate, facilitate, or cooperate
with epigenetic lesions (Figure 4). It has been experi-
mentally proven that both normal and malignant cells
can be reprogrammed into either stem cells or into
different phenotypes. Epigenetic programming is
governed by transcription factors, and it is increasingly
apparent that such proteins are excellent therapeutic
targets. The enzymatic complexes that introduce epige-
netic modifications are also therapeutic targets, and
may be useful to target in cases where transcription
factor targets are unknown or not the primary cause
of aberrant epigenetic patterning. This avenue of re-
search has great potential to overcome the malignant
programming of tumor stem cells and eradicate
MRD, or at least add new selective pressures on the
leukemic cells.SUMMARYAND RECOMMENDEDAREAS OF
INVESTIGATION
Our survey has uncovered the fact that mechanisms
of hematologic relapse following AlloHSCT unrelated
to GVT effects have not been previously studied in
a systematic fashion. Recent studies with relapses in
the haploidentical transplant setting indicate that per-
haps one-third of relapses occur because of immuno-
logic escape by the emergence of acquired uniparental
disomy of chromosome 6p, and fully two-thirds of cases
are probably related and are because of undefined
mechanisms. The recent observation that gain of
function point mutations have been found to cause
resistance in BCR-ABL under imatinib and dasatinib
therapy suggests that nonimmune-based mechanismsof relapse may become even more complex with current
therapies. In the future it may be possible to develop
tailored or ‘‘personalized’’ conditioning regimens that
might mitigate the evolution of resistance to allogeneic
stem cell procedures.
Our committee has outlined a number of promising
areas to investigate what might reveal the source of
resistance to the powerful effects of AlloHSCT. At
this point, there is no systematic approach to study
this clinically important scenario. Factors to be consid-
ered are the possible contributions of host microenvi-
ronments that provide sanctuaries that may harbor or
rescue drug-resistant subclones, to malignancies that
are intrinsically complex and have preexisting subclones
that are destined to survive current conditioning
regimens and the subsequent alloimmune effects.
What is clear is that that the experimental ‘‘toolbox’’
of reagents to address these important issues is not
currently available. One major dearth in our toolbox is
a lack of robust preclinical models for evaluation of reg-
imens that have been demonstrated to be predictive of
therapeutic efficacy in patients, or for the identification
of regimens that may promote resistance. Similarly, the
role of LSCs as they relate to resistance remains to be
clarified. Finally, the most straightforward approach
to uncover mechanisms of relapse would be to prospec-
tively archive specimens of the tumor and host immune
system before and after AlloHSCT. At this point, there
is no incentive or mechanism to develop such a national
registry. Given access to a set of tumor and host immune
systems before and after relapse from AlloHSCT, it is
likely that currently available technologies could
identify critical biomarkers of resistance and point to
the Achilles’ heel in hematologic tumors that would
permit the development of improved personalized
conditioning regimens to prevent relapse.
In summary, 3 broad areas have been highlighted in
this review that require further study to improve our un-
derstanding of how both intrinsic and extrinsic forces on
malignant cells, which occur during and after Al-
loHSCT, affect the incidence of relapse. We have seen
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study rare cell populations, rare genetic and epigenetic
events, and, subsequently, to delineate rare downstream
biochemical pathways that collectively will form a bio-
logic ‘‘fingerprint’’ of the events that increase the poten-
tial for disease relapse. Although some of the technology
exists to address these challenges, new and improved
technologies will need to be developed to isolate and
study rare biologic events. Similarly, as the enormous
amount of genetic, epigenetic, protein, and functional
data is collected and entered into growing databases,
we must apply novel analytical methods to understand
and compare the data. Equally, new mechanisms must
be developed to share with other investigators the mas-
sive amount of data, as well as the analysis and interpre-
tation of that data.
1. Genomic and epigenetic lesions/alterations: ‘‘fitness’’
and natural selection: we must improve our ability to
measure rare events, such as LSCs and genetic and
epigenetic lesions. As the cost of whole genome
sequencing continues to decrease, it will soon be pos-
sible to economically acquire whole DNA and RNA
sequence data, which could be acquired from low-
frequency cell populations such as LSCs. Simulta-
neously, epigenetic information must be acquired
on LSC and total malignant cells and compared to
nonmalignant somatic cells. The role of nucleotide
polymorphisms, of noncoding genes and ncRNA in
leukemogenesis and in the longitudinal progression
of LSC and whole-cell populations needs to be ex-
plored further,which should be combined with whole
genome analysis. As a complement to biologic exper-
imentation, novel bioinformatics methods could be
used to validate or identify new gene interactions
and to identify shared or common nodes in signaling
pathways. The expanding capabilities of distributed
computing networks and robotics could be applied
to this area, which would improve the accuracy and
speed of data acquisition and boost our understand-
ing of the role of these alterations in relapse.
2. Cancer stem cells: leukemia stem cells as a model:
the CSC hypothesis has gained impetus as experi-
mental data continue to emerge, especially in hema-
tologic malignancies where the evidence is the most
compelling. In this hypothesis, a heterogeneous
cancer is sustained by a mostly quiescent subpopula-
tion of cells that are capable of self-renewal and dif-
ferentiation into all cell types found within the
tumor, a scenario somewhat analogous to normal
cellular ontogeny. Nevertheless, the stem cell hy-
pothesis does not exclude the possibility that ac-
quired changes in the genotype and phenotype of
‘‘progeny’’ malignant cells over time might produce
cells that have acquired limited or unlimited self-
renewal capacity. This might occur, for example,
by turning on self-renewal pathways such as Wnt/b-catenin. These issues must be explored with lon-
gitudinal studies of malignant cells from patients
as well as human cells passage in animal models.
We must improve our preclinical in vivo models,
by using the xenograft/NSG mouse model as a per-
missive model for enumerating and expanding
LSCs and by improving the nonhuman primate
models.
3. Therapy resistance mechanisms: therapy resistance
to drugs, radiation, or both, arise frequently from
selection of resistant clones that have acquired
favorable genetic or epigenetic alterations, which
increase the fitness of the cancer cell in the thera-
peutic milieu. Growth factors, cell cycle proteins,
cell death mechanisms, drug efflux mechanisms,
and signaling pathways that are affected by radia-
tion or chemotherapy, such as Notch, p53, bcl-2,
and MDR, need to be studied longitudinally in
LSC and whole-cell populations from patients be-
fore and after stem cell transplantation (SCT). In
addition, the affects of MA versus NMA condition-
ing regimens must be compared, as well as the af-
fects of TBI versus ‘‘targeted’’ radiation such as
total lymphoid irradiation.ACKNOWLEDGMENTS
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